英夫利昔单抗输注反应与IgE抗药抗体无关
该研究开发了含阳性对照的稳健IgE抗药抗体(IgE-ADA)检测方法,在三个回顾性队列(n=159)中检测IgE-ADA,包括输注反应阳性(IR+,n=37)和阴性(IR-,n=39)患者及83例脊柱关节炎纵向血清。结果显示IR-者均无IgE-ADA,IR+者仅4/37(11%)呈低水平(0.1-0.3 IU/mL,低于0.35 IU/mL过敏症状风险阈值),且所有IgE-ADA阳性者同时有(非常)高IgG-ADA水平;英夫利昔单抗治疗的脊柱关节炎患者IgE-ADA发生率估计低于约1%。结论认为IgE-ADA很少检出,且多数IR+患者无IgE-ADA,提示IgE-ADA与输注反应无关。
要点
- IR-患者均未检出IgE-ADA,IR+患者仅11%呈低水平。
- IgE-ADA阳性者均伴(非常)高IgG-ADA水平。
- 脊柱关节炎患者IgE-ADA发生率估计低于约1%。
核心结论
- IgE-ADA在英夫利昔单抗治疗患者中罕见,且与输注反应无关。
研究设计与样本
- 开发重组人IgE抗英夫利昔单抗单克隆抗体作为标准品和阳性对照,建立稳健IgE-ADA检测方法。
- 在三个回顾性队列(n=159)中检测IgE-ADA,包括IR+(n=37)和IR-(n=39)患者及83例脊柱关节炎患者的纵向血清。
主要发现
- IR-患者中0/39检出IgE-ADA,IR+患者中4/37(11%)检出低水平IgE-ADA(0.1-0.3 IU/mL)。
- 所有IgE-ADA阳性患者同时具有(非常)高水平的IgG-ADA。
- 英夫利昔单抗治疗的脊柱关节炎患者中IgE-ADA发生率估计低于约1%。
关键数值与推荐
- IgE-ADA低水平定义为0.1-0.3 IU/mL,低于与过敏症状风险升高相关的0.35 IU/mL阈值。
临床怎么用
- 输注反应发生时不应常规归因于IgE介导的抗药抗体,需结合IgG-ADA等其他因素评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Controversy exists on the role of IgE antidrug antibodies (IgE-ADA) in infusion reactions (IR) on infliximab treatment, partly due to the lack of a positive control used for assay validation. We sought to (1) develop a robust assay to measure IgE-ADA, including a positive control, (2) determine the association between IgE-ADA and IR and (3) determine the incidence of IgE-ADA in infliximab treated patients. METHODS: A recombinant human IgE anti-infliximab monoclonal antibody was developed as standard and positive control. With this antibody, we set up a novel robust assay to measure IgE-ADA. IgE-ADA was determined in three retrospective cohorts (n=159) containing IR+ (n=37) and IR- (n=39), and longitudinal sera of 83 spondyloarthritis. RESULTS: IgE-ADA was found in 0/39 IR-, whereas 4/37 (11%) IR+ showed low levels (0.1-0.3 IU/mL, below the 0.35 IU/mL threshold associated with elevated risk of allergic symptoms). All patients who were IgE-ADA positive also had (very) high IgG-ADA levels. The incidence of IgE-ADA in patients with infliximab-treated spondyloarthritis was estimated at less than approximately 1%. CONCLUSIONS: IgE-ADA is rarely detected in infliximab-treated patients. Moreover, the absence of IgE-ADA in the majority of IR+ patients suggests that IgE-ADA is not associated with infusion reactions.
引用
- van Schie KA, Ooijevaar-De Heer P, Kruithof S, et al. Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies. Ann Rheum Dis. 2017. PMID: 28455438. doi:10.1136/annrheumdis-2016-211035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。